Prosecution Insights
Last updated: April 19, 2026
Application No. 16/061,908

PROCESS FOR DEPIGMENTING KERATIN MATERIALS USING THIOPYRIDINONE COMPOUNDS

Non-Final OA §102§103
Filed
Jun 13, 2018
Examiner
ROGERS, JAMES WILLIAM
Art Unit
1618
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
L'Oréal
OA Round
7 (Non-Final)
46%
Grant Probability
Moderate
7-8
OA Rounds
3y 10m
To Grant
68%
With Interview

Examiner Intelligence

Grants 46% of resolved cases
46%
Career Allow Rate
413 granted / 891 resolved
-13.6% vs TC avg
Strong +22% interview lift
Without
With
+21.6%
Interview Lift
resolved cases with interview
Typical timeline
3y 10m
Avg Prosecution
50 currently pending
Career history
941
Total Applications
across all art units

Statute-Specific Performance

§101
0.2%
-39.8% vs TC avg
§103
41.5%
+1.5% vs TC avg
§102
26.0%
-14.0% vs TC avg
§112
22.6%
-17.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 891 resolved cases

Office Action

§102 §103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . In view of the appeal brief filed on 8/11/2025, PROSECUTION IS HEREBY REOPENED. as set forth below. To avoid abandonment of the application, appellant must exercise one of the following two options: (1) file a reply under 37 CFR 1.111 (if this Office action is non-final) or a reply under 37 CFR 1.113 (if this Office action is final); or, (2) initiate a new appeal by filing a notice of appeal under 37 CFR 41.31 followed by an appeal brief under 37 CFR 41.37. The previously paid notice of appeal fee and appeal brief fee can be applied to the new appeal. If, however, the appeal fees set forth in 37 CFR 41.20 have been increased since they were previously paid, then appellant must pay the difference between the increased fees and the amount previously paid. A Supervisory Patent Examiner (SPE) has approved of reopening prosecution by signing below: /Michael G. Hartley/ Supervisory Patent Examiner, Art Unit 1618 Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale or otherwise available to the public before the effective filing date of the claimed invention. Claim(s) 34-35,39-42 and 49-53 is/are rejected under 35 U.S.C. 102a1 as being anticipated by Marat (US 2013/0315847, cited previously). Marat discloses a process for depigmenting keratin materials using compositions containing thiopyridinone compounds of formula I or II below: PNG media_image1.png 932 450 media_image1.png Greyscale , note the compound above reads on the elected species (compound 1) when R1 is H and R2 is C1 methylene substituted with iv) CONHR3 where R3 is a hydrogen atom. See entire disclosure, especially abstract, [0014]-[0024],[0034]-[0035] and claims 1-4. The closest lead compound to applicants elected compound 1 of claim 1 is considered to be compound 18 of Marat shown below: PNG media_image2.png 204 658 media_image2.png Greyscale , different only by the substitution of an amine group for a hydroxyl (amide to carboxylic acid) from compound 1. As noted in formula I of Marat above ([0020]-[0021]) the saturated linear C1-C20 carbon contains substituents including amide and carboxylic acid, therefore applicants claimed compound 1 containing a carboxylic acid instead of an amide functional group would be readily envisaged by one of ordinary skill in the art of organic chemistry. Since only one functional group is being replaced with another disclosed functional group one of ordinary skill would readily envisage such a possibility. Regarding the amounts of compound in claims 39-42 Marat discloses amounts in particular of 0.5-3 wt%, within the claimed ranges. See [0084]. Regarding the limitation in claim 50 on physiologically acceptable medium, Marat discloses several adjuvants that are claimed including water and organic solvents. See [0087]-[0089] and claims 8-9. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claims 34-35,39-42 and 49-53 is/are rejected under 35 U.S.C. 103 as being unpatentable over Marat (US 2013/0315847, cited previously) in view of Nair et al. (WO 2004/069221), this new rejection was necessitated by amendment. Marat is disclosed above. While the examiner believes the claims would have been readily envisaged by one of ordinary skill and therefore anticipated it also follows that substitution of a carboxylic acid for the amide of compound 18, producing claimed compound 1, would be obvious as these two substituents are clearly taught as alternatives to each other. One of ordinary skill would have a very high expectation of success in making such a modification since both functional groups are clearly taught and equivalent. Thus, the claimed invention would have been prima facie obvious since all the claimed elements were known in the prior art and one skilled in the art could have combined the elements as claimed by known methods with no change in their respective functions and the combination would have yielded predictable results to one of ordinary skill in the art at the time of the invention. Furthermore the following compound taught by Marat: PNG media_image3.png 262 418 media_image3.png Greyscale , is nearly the same as compound 3 recited in claim 1 and compound 1 in claim 50: PNG media_image4.png 119 552 media_image4.png Greyscale , except for the substitution of a methyl for hydrogen. See compound 28 on page 8 and claim 5. To substitute these homologs would be obvious to one of ordinary skill in the art. With regard to substitution group hydrogen versus methyl group, it is well established that the substitution of methyl for hydrogen on a known compound is not a patentable modification absent unexpected or unobvious results. In re Wood, 199 U.S.P.Q. 137 (C.C.P.A. 1978) and In re Lohr, 137 U.S.P.Q. 548, 549 (C.C.P.A. 1963). The claimed compounds are so closely related structurally to the homologous compounds of the reference as to be structurally obvious therefore in the absence of any unobviousness or unexpected properties. Response to Arguments Applicant's arguments filed 8/11/2025 have been fully considered but they are not persuasive. Applicants assert the examiner has not established a prima facia case of anticipation as Marat discloses a broad genus of compounds possible from the various R groups. Applicants assert the examiner has not identified how Marat would allow one of ordinary skill to envisage each group in the limited manner claimed. As noted in the modified rejection above when one of ordinary skill considers the lead compound 18 of Marat, they would readily envisage substitution of the amide group with a carboxylic acid as this possibility is clearly defined in the abstract and claims. Since only one functional group is being replaced with another disclosed functional group one of ordinary skill would readily envisage such a possibility. The claims are also considered obvious over Marat as detailed above. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to JAMES W ROGERS whose telephone number is (571)272-7838. The examiner can normally be reached 9:30-6:00 PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Michael Hartley can be reached at 571-272-0616. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /JAMES W ROGERS/Primary Examiner, Art Unit 1618
Read full office action

Prosecution Timeline

Jun 13, 2018
Application Filed
Apr 02, 2020
Non-Final Rejection — §102, §103
Oct 08, 2020
Response Filed
Nov 20, 2020
Final Rejection — §102, §103
May 24, 2021
Notice of Allowance
Dec 24, 2021
Request for Continued Examination
Jan 02, 2022
Response after Non-Final Action
Feb 23, 2022
Non-Final Rejection — §102, §103
Jul 28, 2022
Response Filed
Aug 26, 2022
Final Rejection — §102, §103
Mar 08, 2023
Notice of Allowance
May 08, 2023
Request for Continued Examination
May 15, 2023
Examiner Interview Summary
May 15, 2023
Response after Non-Final Action
May 15, 2023
Response after Non-Final Action
May 15, 2023
Applicant Interview (Telephonic)
Sep 07, 2023
Non-Final Rejection — §102, §103
Mar 12, 2024
Notice of Allowance
Oct 15, 2024
Request for Continued Examination
Oct 17, 2024
Response after Non-Final Action
Nov 08, 2024
Final Rejection — §102, §103
Mar 13, 2025
Notice of Allowance
Aug 11, 2025
Response after Non-Final Action
Oct 14, 2025
Non-Final Rejection — §102, §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12594345
DEGRADABLE HYALURONIC ACID HYDROGELS
2y 5m to grant Granted Apr 07, 2026
Patent 12582727
CHEMILUMINESCENT AND FLUORESCENT NANOPARTICLE FOR OPTICAL IMAGING OF CANCER
2y 5m to grant Granted Mar 24, 2026
Patent 12582744
DRESSINGS COMPRISING PLATELET LYSATE
2y 5m to grant Granted Mar 24, 2026
Patent 12565506
NITROGEN-CONTAINING MACROCYCLIC CONJUGATES AS RADIOPHARMACEUTICALS
2y 5m to grant Granted Mar 03, 2026
Patent 12544335
TREATMENT APPROACH BY TARGETED DELIVERY OF BIOACTIVE MOLECULES
2y 5m to grant Granted Feb 10, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

7-8
Expected OA Rounds
46%
Grant Probability
68%
With Interview (+21.6%)
3y 10m
Median Time to Grant
High
PTA Risk
Based on 891 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month